SQZ Biotechnologies Company
SQZB
$0.02
$0.00-4.17%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -44.62% | -32.84% | -24.08% | -20.74% | 26.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.62% | -32.84% | -24.08% | -20.74% | 26.99% |
| Cost of Revenue | -28.67% | -17.11% | -7.55% | 1.19% | 8.90% |
| Gross Profit | 21.79% | 9.86% | -0.91% | -14.99% | -2.60% |
| SG&A Expenses | -24.43% | -19.07% | -6.88% | 2.33% | 10.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.50% | -17.65% | -7.37% | 1.50% | 9.35% |
| Operating Income | 22.72% | 13.12% | 1.87% | -10.26% | -5.27% |
| Income Before Tax | 7.84% | 8.90% | -2.33% | -15.60% | -4.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 7.84% | 8.90% | -2.33% | -15.60% | -4.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.84% | 8.90% | -2.33% | -15.60% | -4.32% |
| EBIT | 22.72% | 13.12% | 1.87% | -10.26% | -5.27% |
| EBITDA | 23.82% | 13.61% | 2.29% | -10.00% | -5.58% |
| EPS Basic | 10.86% | 12.77% | 1.34% | -10.98% | 13.31% |
| Normalized Basic EPS | 26.47% | 18.76% | 7.56% | -4.36% | 13.31% |
| EPS Diluted | 10.86% | 12.77% | 1.34% | -10.98% | 13.31% |
| Normalized Diluted EPS | 26.47% | 18.76% | 7.56% | -4.36% | 13.31% |
| Average Basic Shares Outstanding | 3.57% | 4.53% | 3.94% | 4.49% | 15.46% |
| Average Diluted Shares Outstanding | 3.57% | 4.53% | 3.94% | 4.49% | 15.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |